

C.E. Unterberg Towbin
Emerging Growth Opportunities Conference
July 11, 2007

Forward Looking Statements

Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to obtain additional financing and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.



- Develops, manufactures and markets rapid tests for the detection of HIV and other infectious diseases using In-licensed single path lateral flow (SPLF) platforms
- Rapid HIV tests were FDA PMA approved in 2006 for US and Marketed by Inverness Medical Innovations
- March 2007 Patent Issued for Dual Path Platform (DPP™) technology for Next Generation of Point of Care Testing (POCT)
- June 2007 USDA Issued Product and Facility License
- Strong Sales Growth Continuing in 2007 YTD
- FDA & USDA-Licensed manufacturing facility in Long Island with approximately 100 Employees

Chembio's Market, Point of Care (POC) is the Place to Be in IVD

<i>Size of US and Global Point of Care Markets (Billions)</i>	<i>United States</i>	<i>Global</i>
2000	\$0.9	\$2.5
2005	\$1.9	\$4.0
2008	\$2.4	\$5.2

- **POCT is Fastest Growing Segment of \$28B In-Vitro Diagnostics Market**
- **Significant Consolidation/M&A Activity**
 - **Valuation Premiums**


Why the Growth in POCT?

- Improved Detection Systems (e.g.; DPP™)
- Technologies for Data Recording, Analysis, Communication
- Consumer Need for Quick Results
- Drive For Costs Containment




Our FDA Approved HIV Tests Are Marketed in the U.S. by the World's Largest POCT Company: Inverness Medical Innovations Inc. (IMA)

HIV 1/2 Infectious Disease



Clearly different.
Clearly better.



Women's Health | Infectious Disease | Cardiovascular | Drugs of Abuse | GI Disorders

Clearview[®] HIV 1/2 STAT-PAK[™]

Clearview HIV 1/2 STAT-PAK
A rapid, qualitative screening test for the detection of antibodies to HIV 1 and HIV 2 in human whole blood, serum, and plasma.



HIV 1/2 Infectious Disease



Clearly different.
Clearly better.




Women's Health | Infectious Disease | Cardiovascular | Drugs of Abuse | GI Disorders

Point of Care Diagnostics

Clearview[®] COMPLETE HIV 1/2

Clearview COMPLETE HIV 1/2
A single-use, self-contained, closed system for the collection, processing, and analysis of a whole blood, serum or plasma sample for the detection of HIV 1 and HIV 2 antibodies.




Point of Care Diagnostics

Clearly different[™]
Provides IgG immunodiffusion

- Rapid Rx
- Convenient bandage
- Reliability performs
- Flexibility whole kit

5 FINGERSTICK SAMPLE

To sample from a fingerstick:
Draw fingerstick blood sample using the lancet provided. Wipe away first drop of blood.
Collect second drop of blood, filling the narrow sampling tip of the device as shown.



- Launched Q1 2007
- License to Inverness SPLF Patents for Other Chembio Products
- Hospital Market
- Physicians Office Labs
- Public Health
- Potential OTC through IMA JV with P&G

Ex-US Chembio is Collaborating with Leading Global Health Organizations

- **Brazilian Ministry of Health**
- **The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)**
- **Clinton Foundation HIV/AIDS Initiative**
- **CDC (Center for Disease Control and Prevention)**
- **Infectious Disease Research Institute**



Our NY Manufacturing Facility Can Serve All POC Markets



Class III Biologics
- HIV, HCV



Veterinary Diagnostics



ISO 13.485 for Global Marketplace




Chembio's First USDA
Approval was Received in
June 2007 for its Veterinary
Tuberculosis Test

Our Single Path Lateral Flow (SPLF) Technology Know-How...




...Benefits Our Newly Patented Dual Path Platform (DPP™) R&D



What is Dual Path Platform (DPP™)?

- Platform for Next Generation POCT
- Enables Improved Sensitivity, Multiplexing, Sample Control and Quantitative Measurement vs. Conventional SPLF
- Uses standard SPLF Equipment
- Free of all SPLF IP
- **Opening the Door For Some Exciting New Product Collaborations**



DPP™ Cassette




**Inside a
Conventional
SPLF Cassette**


Chembio Has a Pipeline of Several New Tests Based Upon the DPP™ Platform

- Our strategy is to leverage our expertise in lateral flow technology product development and regulated manufacturing with our New Intellectual Property
- We are Seeking Collaborations with Leading Organizations on the Development of New DPP™ Rapid Test Products as follows:
 - Tests for Blood Born Pathogens
 - ✓ HIV, Hepatitis C, Chagas, Syphilis
 - Respiratory Tests
 - Bacterial Contamination Tests
 - ✓ Blood Products
 - ✓ Environmental & Food safety


Multiplexing with DPP™: HIV 1/2 CONFIRMATORY TEST



1. Add 10 µl of serum/blood to the sample well (S+B).




2. Add 1 drop (30 µl) of buffer to the sample well (S+B).




3. Add 3 drops (90 µl) of buffer to the buffer well (B) when the colored lines disappear completely.

4. Read the results at 20 minutes
Negative result: one line



Negative Result


Positive result indicates presence of antigen or antigens (two - six lines)



HIV1 Positive Result
(At least two HIV1 antigens reactive)



HIV2 Positive Result
(Only the HIV2 antigen reactive)



HIV 1/2 Positive Result
(At least two antigens for HIV1 and the HIV2 antigen all reactive)

Selected Financial Information

Chembio Diagnostics, Inc. \$(000s)	2005	2006	2006 Q- 1 (unaudited)	2007 Q- 1 (unaudited)
Net Sales	3,360	6,294	1,169	2,025
Total Revenues	3,941	6,502	1,238	2,038
Gross Profit	1,332 34%	2,017 31%	436 35%	660 32%
SG& A	3,265	5,195	1,298	1,252
R&D Expenses	1,365	1,401	393	319
Net Loss	(3,252)	(4,995)	(1,264)	(729)
Net Loss Attributable to Stockholders	(6,769)	(8,205)	(1,940)	(1,083)
HIV Test Revenues (unaudited)	2,400	4,434	538	1,811
Chagas Test Revenues (unaudited)	69	1,217	484	5

Capitalization

AS OF 06/30/2007			TOTAL COMMON
Common Shares			12,644,310
Convertible Preferred Shares			
Series A	141.6	CONVERTIBLE INTO	7,079,506
Series B	112.3	CONVERTIBLE INTO	9,202,508
Series C	165.0	CONVERTIBLE INTO	10,312,500
			39,238,824
Options:			
	\$ 0.647		2,540,625
Warrants:			
	\$ 0.785		26,196,085
			67,975,534

Inverness invested \$2MM in Series C round completed in late 2006

Senior Management Team

<i>Name</i>	<i>Position</i>	<i>Year Joined Company</i>	<i>Relevant Experience</i>
Lawrence Siebert	CEO & Chairman	1992 2002	JD, Private Equity, LBOs Became CEO in 2002
Javan Esfandiari	SVP R&D	2000	Sinovus Biotech/Svanova Joined Chembio in 2000 Inventor of DPP™
Richard Larkin	CFO	2003	CPA, MRP Systems
Robert Aromando	SVP Comm.	2007	Roche /30 Years Industry Experience

Key Milestones: June 2006-2007

- **Increased Participation in Expanding Global Market For Rapid HIV Tests**
 - Global Agreement with Inverness Medical
 - National Screening Programs in Mexico & Nigeria
- **Delivered 750K Chagas STAT-PAK™ to First-Ever National Screening Program in Latin America**
 - Increased Attention to Chagas in Developed World
- **Granted DPP™ Patent**
 - Significant Amount of Business Development Activity
- **Received USDA License for Vet-TB Test**
- **Annual and Quarterly Growth Toward Profitability**

Milestones 2007-2008

- **Revenue Increases, Higher Margin Product Sales Mix Leading to Profitability**
 - US Market Entry by IMA with Chembio HIV Tests
 - Revenue Increases from Ex-US Markets for HIV Tests
 - ISO/CE
- **Veterinary Products Launch**
 - USDA Approvals and Market Launches for Vet-TB Tests
- **New Infectious/Neglected Disease Rapid Tests**
 - Syphilis, Chagas, Leishmania, Tuberculosis
- **Dual Path Platform™ Developments**
 - New Collaborations and Licenses with Market Leaders